By Kurt Orzeck (March 7, 2014, 8:15 PM EST) -- A Pennsylvania trial jury on Friday returned a $3 million verdict against a Johnson & Johnson unit in a case accusing the company of failing to warn a woman of the risk of birth defects when using its anti-epilepsy drug Topamax during pregnancy.
Attorneys representing the Wisconsin family of 5-year-old Payton Anderson had told the Philadelphia County Court of Common Pleas on Tuesday that Janssen Pharmaceuticals Inc. didn't update Topamax's label to reflect data showing that the drug resulted in increased incidents of cleft lips and cleft palates in newborn babies.
The family filed suit in December 2011 alleging the child...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!